Treatment for dark adaptation

US7470660B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Daniel M. Schwartz · San Francisco, US
• Keith Duncan · San Francisco, US
• Kathy Bailey · San Francisco, US
• John P. Kane · Tafton, US
• Brian Ishida · Walnut Creek, US

Key dates

• Filing date: Feb 10, 2005
• Grant date: Dec 30, 2008
• Expiry date: Mar 7, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P27/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention addresses the treatment of age-related macular degeneration, and treatment of individuals with impaired visual function such as impaired dark adaptation, using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration and improving impaired dark adaptation. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.